There is a risk of users making adjustments during treatment that are unnecessary. The FDA is still evaluating the issue at this time.

Medtronic has held a minority investment in CathWorks for several years, and the two organizations entered into a co-promotion agreement in 2022. Once finalized, the move will increase Medtronic's presence in the cath lab. 

Abbott first warned the public about this problem in November. Now, for the second time in less than a month, the FDA is providing additional details. 

Researchers explored data from more than 1,000 patients with calcified coronary artery disease who required plaque modification. IVL and atherectomy were linked to comparable success rates, but adverse events were less likely with IVL.

Several detachable coil systems are being recalled due to a higher-than-expected failure to detach rate. Customers should not use them going forward.

STS late-breaking study found BITA and SITA+RA have similar long-term survival, but age plays a role in which to choose.

The Amend device from Valcare Medical has a closed ring shape similar to the annuloplasty rings used to treat MR during open-heart surgeries. These early patients will be followed for a total of five years.

New drug allows patients to self-treat PSVT. About 2 million people in the U.S. have been diagnosed with condition.

Nina Goodheart, the president of Medtronic’s structural heart and aortic business, has announced her retirement. 

The interventional treatment of tricuspid valve disease has evolved in recent years thanks to new research and critical FDA approvals. Cardiologist Ryan Kaple, MD, reviewed this trend for a new video interview.